Drugs / CellREADY® drug product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07367815 | May 2026 → May 2029 expected | Alzheimer disease | University Hospital, Toulouse | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CellREADY drug product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07367815 ↗ |
| Known as | AdMSC | “Allogeneic AdMSC (CellREADY® drug product), intravenous administration, dose of 50 millions.” NCT07367815 ↗ |
| Route | Intravenous | “intravenous administration” NCT07367815 ↗ |